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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease of aging and
currently has no cure. Its onset and progression are influenced by multiple factors.
There is growing consensus that successful treatment will rely on simultaneously
targeting multiple pathological features of AD. Polyphenol compounds have many
proven health benefits. In this study, we tested the hypothesis that combining three
polyphenolic preparations (grape seed extract, resveratrol, and Concord grape juice
extract), with different polyphenolic compositions and partially redundant bioactivities,
may simultaneously and synergistically mitigate amyloid-β (Aβ) mediated neuropathology
and cognitive impairments in a mouse model of AD. We found that administration
of the polyphenols in combination did not alter the profile of bioactive polyphenol
metabolites in the brain. We also found that combination treatment resulted in better
protection against cognitive impairments compared to individual treatments, in J20 AD
mice. Electrophysiological examination showed that acute treatment with select brain
penetrating polyphenol metabolites, derived from these polyphenols, improved oligomeric
Aβ (oAβ)-induced long term potentiation (LTP) deficits in hippocampal slices. Moreover, we
found greatly reduced total amyloid content in the brain following combination treatment.
Our studies provided experimental evidence that application of polyphenols targeting
multiple disease-mechanisms may yield a greater likelihood of therapeutic efficacy.
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INTRODUCTION
Alzheimer’s disease (AD) is a devastating disorder that strikes 1
in 10 Americans over the age of 65 and almost half of Americans
over 85. The odds of developing AD doubles every 5 years after
individuals reach the age of 65. There are approximately 35 mil-
lion US citizens that are 65 years of age or older who are at risk of
developing AD, representing 13% of the population. This number
will grow dramatically in the coming decades, reaching 17% of the
population by the year 2020. Despite tremendous effort to find a
cure and effective treatments for the disease, currently available
therapies only modestly improve cognitive function and have no
effect on disease progression.
Polyphenolic compounds have been increasingly viewed
as natural sources for treating numerous illnesses, includ-
ing neurological disorders, due to their strong antioxidant,
anti-inflammatory, anti-microbial, and anti-tumor activities.
Mounting evidence suggests that polyphenolic compounds, from
a variety of diverse sources, are able to improve cognitive
function and reduce brain neuropathology in animal models
of AD through multiple mechanisms (Rezai-Zadeh et al., 2005;
Ringman et al., 2005; Hartman et al., 2006; Vingtdeux et al.,
2008; Wang et al., 2008; Thomas et al., 2009; Wang et al.,
2009). Our laboratory and others have shown that grape seed
extracts (GSE) rich in proanthocyanidins (PACs) are capable
of modulating AD phenotypes through interfering with aggre-
gation of β -amyloid (Aβ) peptides into neurotoxic, soluble
high-molecular weight Aβ species (Wang et al., 2008, 2009).
We also found that some of the PAC metabolites, such as
methyl-epicatechin glucuronide, can effectively promote basal
synaptic transmission (BST) and long-term potentiation (LTP)
through mechanisms associated with cAMP response element
binding protein (CREB) signaling (Wang et al., 2012). Vingtdeux
and colleagues demonstrated that dietary supplementation with
resveratrol is effective in attenuating the development of Aβ
neuropathology in transgenic AD mouse models. Resveratrol
may modulate Aβ metabolism through AMP-activated protein
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kinase (AMPK) signaling mechanism (Vingtdeux et al., 2010).
Resveratrol also exerts its anti-inflammatory activity against Aβ-
triggered microglial activation via mechanisms involving the
TLR4/NF-κB/STAT signaling cascade (Capiralla et al., 2012).
Polyphenol components from red wine and grape juice have also
been shown to interfere with Aβ generation and Aβ aggrega-
tion (Wang et al., 2006; Ho et al., 2009, 2013). Concord grape
juice supplementation in elderly individuals with mild cognitive
impairment (MCI) was shown to be beneficial in improving their
memory function (Krikorian et al., 2010).
For the past two decades, the majority of AD research has
been conducted based on the amyloid hypothesis that deposi-
tion of Aβ peptides is the central event for AD pathogenesis
(Hardy and Higgins, 1992). Moreover, current drug discovery
strategies are mainly targeting various forms of Aβ. The amy-
loid hypothesis probably holds true for the genetic form of
early-onset AD, which accounts for less than 1% of AD cases.
However, mechanisms underlying late-onset sporadic AD cannot
be explained solely, if at all, by the amyloid hypothesis. Recent
genomewide association studies failed to identify polymorphisms
in genes associated with APP processing (APP, β- or γ-secretase)
and late-onset AD (Gerrish et al., 2012). Moreover, none of the
clinical trials targeting various forms of Aβ or APP process-
ing pathways (e.g., Solanezumab, Bapineuzumab, Intravenous
Immunoglobulin IVIg, Tramiprosate, Tarenflurbil, Semagacestat)
have been successful (Green et al., 2009; Aisen et al., 2011;
Doody et al., 2013, 2014; Salloway et al., 2014). It is possible that
since neurodegeneration starts 20 years before clinical manifesta-
tion, the anti-Aβ intervention is initiated too late to be effective
(Selkoe, 2011; Sperling et al., 2011). However, there is increas-
ing realization that AD is not the result of a single cause, but
rather multiple mechanisms may synergistically contribute to the
onset and progression of the disease (Blennow et al., 2006; Krstic
and Knuesel, 2013). For example, inflammation is known to play
an important role in AD pathologic mechanisms and is likely
a key factor contributing to the onset and progression of AD
(Aisen and Davis, 1994; Akiyama et al., 2000; Smith et al., 2000;
Krstic et al., 2012; Kumar and Foster, 2013). Krstic et al., demon-
strated that chronic inflammation induced by polyriboinosinic-
polyribocytidillic acid (Poly I:C) injection led to age-dependent
development of an AD-like phenotype in wild type mice (Krstic
et al., 2012). More recently, studies demonstrated, in aging rats,
that redox regulation can also directly influence N-methyl-D-
aspartate receptor (NMDAR) function (Kumar and Foster, 2013),
which plays an important role in synaptic plasticity and cognitive
function; its function declines during aging and disease condi-
tion (Barnes et al., 1997). Individual polyphenolic preparations,
such as resveratrol, GSE, or Concord grape juice, have the poten-
tial to modulate AD neuropathology and cognitive dysfunction
through multiple mechanisms, including modulating oxidation
and inflammation, modulating Aβ metabolism, catabolism and
oligomerization, or directly influencing brain activities. In this
study, we test whether combining these three polyphenolic prepa-
rations, with their different polyphenolic compositions and par-
tially redundant bioactivities, provides a safe and effective means
to simultaneously and synergistically mitigate Aβ -mediated neu-
ropathology and cognitive impairments in the brain.
METHODS
CHEMICALS AND MATERIALS
Food grade resveratrol was purchased from ChromaDex (Irvine,
CA). GSE was purchased from supplement Warehouse (UPC:
603573579173). Only one lot of the resveratrol and one lot
of the GSE were used for this particular study. Both resvera-
trol and GSE have been shown to be very stable when stored
at 4◦C in dark. Welch Concord purple grape juice was pur-
chased at a local market and concentrated by solid phase
extraction (SPE), as previously described, to produce Concord
Grape Juice total polyphenol extract (Ho et al., 2009). The
polyphenol profile of this juice extract was confirmed by LC-
MS analysis and previously reported (Xu et al., 2011). Total
polyphenol content was determined to be 62mg of gallic
acid equivalents per mL extract, with principal components
including anthocyanins, PAC oligomers, phenolic acids, and
quercetin glycosides. The juice extract was stored at −20◦C in
the dark and was diluted to the desired concentration once
every 3 days. (+)-catechin, (−)-epicatechin, quercetin-3-O-
glucoside, quercetin-3-O-glucuronide, and quercetin standards
were purchased from Sigma Chemical Co. (St. Louis, MO).
Malvidin-3-glucoside chloride and cyanidin-3-glucoside chloride
were purchased from ChromaDex (Irvine, CA). All extraction
and LC solvents were HPLC certified and were obtained from J.T.
Baker (Phillipsburg, NJ).
PLASMA PHARMACOKINETICS (PK) AND BRAIN ACCUMULATION OF
POLYPHENOL METABOLITES FOLLOWING REPEATED DOSING WITH
COMBINATION TREATMENT OF GSE, CONCORD JUICE EXTRACT, AND
RESVERATROL
Plasma PK and brain bioavailability studies were conducted using
male Sprague-Dawley (SD) rats. SD rats were obtained from
Harlan Sprague Dawley Inc. (Indianapolis, IN) and placed on
a polyphenol free AIN-93M diet (Dyets, Bethlehem, PA), given
deionized water ad lib, and allowed to acclimate for 3 days.
Following the acclimation period, rats were given a combina-
tion of resveratrol, GSE and Concord juice extract (referred to as
Comb), by intragastric gavage using plastic feeding tubes (Instech
FTP-15-78, Plymoth Meeting, PA) for 10 days. To reach proper
dosage, rats were gavaged twice a day, with 8 h separation. The
non-treatment group was gavaged with water. Two days prior to
PK studies, rats were anesthetized by a dose 3–5% of isoflurane
in the anesthesia chamber and maintained with a mask of 1.5–3%
isoflurane. A polyethylene catheter was implanted into the jugular
vein. Rats were injected with Buprenex (0.01–0.05mg/kg) before
regaining consciousness to alleviate pain and allowed to rest for
24 h after surgery. Catheters were kept patent by flushing with
heparinized saline (100 units/mL) every 12 h. Prior to initiation
of PK studies, rats fasted for 8 h. PK assessment was conducted
on the 10th day of gavage by collecting 400μL of blood at base-
line (prior to gavage), 0.25, 0.5, 1, 2, 4, 6, 8 h postgavage from
the jugular catheter into heparinized tubes. Food was offered at
2 h following initiation of PK studies. Fresh blood was processed
to plasma by centrifugation at 5500 rpm for 10min at 4◦C, acidi-
fied with saline (1% ascorbic acid wt/v) in 4:1 ratio, purged with
N2, and stored at −80◦C until analysis. The day after PK, rats
were given a last dosage of treatment, anesthetized, and perfused
Frontiers in Aging Neuroscience www.frontiersin.org March 2014 | Volume 6 | Article 42 | 2
Wang et al. Polyphenols as novel therapeutic agent in AD
with cold physiological saline. The brains were harvested, placed
in 0.2% ascorbic acid in saline, and stored at−80◦C until analysis.
ANALYSIS OF POLYPHENOL METABOLITES
Acidified plasma samples were thawed and brought up to 0.5mL
with acidified saline (0.1% formic acid v/v). Polyphenol metabo-
lites from plasma and brains were extracted using SPE as pre-
viously described (Vingtdeux et al., 2010; Wang et al., 2012;
Ho et al., 2013). Polyphenol metabolites were extracted with
methanol and dried under vacuum. Dried residues were recon-
stituted with 0.1% aqueous formic acid (v/v), loaded on the
preconditioned SPE cartridge, eluted with methanol, and dried.
The dried phenolic extracts were then reconstituted with 0.1%
aqueous formic acid (v/v) and 0.1% formic acid in acetonitrile
(v/v) in 4:1 ratio and sonicated, followed by LC-MS/MS analysis.
Analysis of all polyphenol metabolites and quercetin metabo-
lites and PAC derivatives was performed on an Agilent 6400 Triple
Quad under multiple reaction monitoring modes (MRM). Both
systems were equipped with an ESI source. A Waters XTerra RP-
C18 column (2.1 × 100mm, 3.5μm particle size) was used on
all analysis. A binary mobile phase system, consisting of mobile
phase A: 0.1% aqueous formic acid (v/v) and B: 0.1% formic
acid in acetonitrile (v/v), was used for analysis of monomeric
PACs, resveratrol, and quercetin metabolites. The column was
heated to 30◦C and the system flow rate was 0.3mL/min. Gradient
conditions were: 10% B at 0min, 40% B at 5.5min, 70% B
at 7min, 95% B at 7.5min and back to 10% B at 8.5min to
13.5min. Mass spectra was obtained under negative polarity
scanning between 100m/z-1000m/z on MS-TOF. MRM mass
transitions were 479 → 303 for MeO-EC glucuronides, 465
→ 289 for EC-glucuronides, 289 → 137 for EC, 403 → 227
for resveratrol-glucuronide, and 227 → 143 for resveratrol under
negative polarity on Triple Quad.MRMmass transitions were 493
→ 317 for MeO-quercetin glucuronide, 479 → 303 for quercetin
glucuronide, and 301 → 153 for quercetin aglycone under pos-
itive polarity. Fragmentor voltage was set at 135V and collision
energy was 30 eV for quercetin aglycone and 17 eV for all other
mass transitions. ESI source condition was described as followed:
gas temp was 350◦C, drying gas flow was 11 l/min, nebulizer
was 30 psi, sheath gas temp was 350◦C, sheath gas flow was 11
l/min, capillary voltage was 3500V, and nozzle voltage was 1000V.
Quantification of PACmetabolites and resveratrol were estimated
using calibration curves from parent catechin, epicatechin, and
resveratrol, respectively. Quantification of quercetin metabolites
was accomplished using a calibration curve constructed with
quercetin-3-O-glucuronide standard. For anthocyanin analysis,
the binary mobile phases were A: 2% aqueous formic acid (v/v)
and B: 0.1% formic acid in acetonitrile (v/v). The gradient used
to elute anthocyanins was: 5% B at 0min, 10% B at 10min,
25% B at 30min, 5% B at 31min, and continue at 5% B until
35min. Mass spectra was obtained under positive polarity. ESI
source condition setting was the same as described above. MRM
transitions were: 493 → 331 for malvidin-3-O-glucoside, 479
→ 317 for petunidin-3-O-glucoside, 465 → 303 for delphinidin-
3-O-glucoside, 463 → 301 for peonidin-3-O-glucoside, and
449 → 287 for cyanidin-3-O-glucoside. Quantification of all
anthocyanin glucosides, except for cyanidin-3-O-glucoside, was
estimated using calibration curves of malvidin-3-O-glucoside.
Quantification of cyanidin-3-O-glucoside was achieved by a cali-
bration curve constructed with cyanidin-3-O-glucoside standard.
AD MICE AND TREATMENT
Female J20 AD transgenic mice, expressing human amyloid
precursor protein (APP) containing both the familial AD
Swedish (K670N/M671L) and the Indiana (V717F) mutations
(APPSwInd) under the human platelet-derived growth factor beta
polypeptide (PDGFB) promoter (Mucke et al., 2000), were pur-
chased from the Jackson Laboratory. All mice were housed with
food and water available ad libitum and maintained on a 12:12-h
light/dark cycle with lights on at 07:00◦ h in a temperature-
controlled (20 ± 2◦C) room prior to experimental manipulation.
All procedures and protocols were approved by the Icahn School
of Medicine at Mount Sinai’s Institutional Animal Care and
Use Committee (IACUC) through the Center for Comparative
Medicine and Surgery. Mice were randomly grouped into 5
groups, the non-treated control group (CTRL); the resveratrol-
treated group (Resv): 400mg/kg/day mixed with food; the GSE-
treated group (GSE): 200mg/kg/day mixed with food; the juice
extract-treated group (Juice): 183mg/kg/day total polyphenol;
and the group treated with the combination of resveratrol, GSE,
and juice (Comb). The doses chosen for each component was
based on equivalent doses used in studies that showed efficacy
either in human or animal models (Lagouge et al., 2006; Wang
et al., 2008, 2010; Krikorian et al., 2010; Vingtdeux et al., 2010).
The treatment started at 3 months of age and the animals were
treated for 7 months.
BEHAVIORAL ASSESSMENT OF COGNITIVE FUNCTIONS BY THE
MORRIS WATER MAZE TEST
Spatial learning memory was assessed by the Morris water maze
(MWM) behavioral test, as previously described (Morris, 1984;
Wang et al., 2007). Mice were tested in a circular pool filled with
water mixed with non-toxic white paint (Dick Blick ArtMaterials,
IL). In the initial learning phase, mice were trained for 7 consec-
utive days, which allowed them to learn to escape from the water
onto a hidden/submerged (1.5 cm below-water surface) escape
platform (14 × 14 cm) in a restricted region of the pool using
the spatial cues provided. Spatial learning memory is assessed by
recording the latency time for the animal to escape from the water
onto the submerged escape platform as a function of the number
of learning trials during the learning phase. Twenty-four hours
after the last learning session, mice were subjected to a 45 s probe
trial wherein the escape platform was removed. Spatial mem-
ory retention is reflected by the percentage of time animals spent
within the “target” quadrant of the pool that previously contained
the hidden escape platform. Water maze activity during training
and probe trials was monitored with the San Diego Instrument
Poly-Track video tracking system (San Diego, CA).
ASSESSMENT OF AD-TYPE AMYLOID NEUROPATHOLOGY
Total Aβ1−40 or Aβ1−42 in the brain was quantified by sand-
wich ELISA (BioSource, Camarillo, CA), as previously described
(Wang et al., 2005). Plaque burden was analyzed as previ-
ously described (Wang et al., 2005). Briefly, tissue was fixed
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with 4% paraformaldehyde in phosphate buffer and 0.125%
glutaraldehyde. Fixed brain hemispheres were sectioned on a
Vibratome at 50μm and stained with thioflavin-S. Micrographs
were taken and plaque burden was quantified using Image J soft-
ware that converts micrograph to binary images for plaque
number and plaque area assessment.
ELECTROPHYSIOLOGICAL RECORDINGS
Wild type mice were sacrificed by decapitation and the brains
were quickly removed. Hippocampal slices (350μm) were made
and placed into oxygenated artificial cerebrospinal fluid (ACSF)
at 29◦C for a minimum of 90min to acclimatize. Slices were
then transferred to a recording chamber (Fine Science Tools
Inc, CA, USA) and perfused continuously with oxygenated-ACSF
at 32◦C. Slices were treated with 200nM oligomeric Aβ in the
presence or absence of 300 nM of 3′-O-methyl-epicatechin-O-
β-Gluc, 300 nM of cyanidin-3-O-Glc, or 20μM resveratrol for
60min before transferring to the recording chamber. The use of
20μM resveratrol is based on the in vitro activation of AMPK
study (Vingtdeux et al., 2010). For extracellular recordings: CA1
field excitatory postsynaptic potentials (fEPSPs) were recorded
by placing stimulating and recording electrodes in CA1 stra-
tum radiatum as previously described (Gong et al., 2004). BST
was not assayed in this particular study because previous stud-
ies demonstrated that oligomeric Aβ inhibits LTP in the CA1
region of mouse hippocampal slices without affecting BST (Wang
et al., 2002; Olsen and Sheng, 2012). For LTP experiments, a
40–60min baseline recording period preceded the θ-burst stimu-
lation. Baseline was recorded every min at an intensity that evokes
a response ∼35% of the maximum evoked response. LTP was
induced using θ-burst stimulation (4 pulses at 100Hz, with the
bursts repeated at 5Hz and each tetanus including three 10-burst
trains separated by 15 s) and fEPSPs were monitored for up to
140min to assess the magnitude of potentiation.
STATISTICAL ANALYSIS
Data was analyzed using SPSS program or Prism software (V4.03,
GraphPad Software, Inc, San Diego, CA). Data was presented as
mean ± s.e.m. and analyzed using Two-Way ANOVA in a within-
subjects design, Two-Way ANOVA with repeated measure, or
One-Way ANOVA, followed by Dunnett’s multiple comparison,
2-tailed student t-test (if sample sizes are equal), or Aspin-Welch
procedure (if the sample sizes or standard deviations differed).
For electrophysiology study, significant differences were set to
∗p < 0.05, ∗∗p < 0.01, and for others, ∗p < 0.0125 (p < 0.05
adjusting for 4 comparisons), ∗∗p < 0.0025 (p < 0.01 adjusting
for 4 comparisons).
RESULTS
COMB TREATMENT DOES NOT CHANGE PLASMA PK RESPONSE OR
BRAIN PROFILE OF POLYPHENOL METABOLITES
To test whether polyphenols delivered in combination would
change the brain bioavailability, we treated the SD rats with Comb
and assessed the plasma PK and brain polyphenol metabolites’
profiles and compared these profiles with those from previous
studies on individual polyphenol preparation (Vingtdeux et al.,
2010; Wang et al., 2012; Ho et al., 2013). Consistent with previous
findings (Wang et al., 2008; Vingtdeux et al., 2010), all metabo-
lites were found in the plasma and brain following 10-day Comb
treatment: catechin and epicatechin from GSE led to the accumu-
lation of PAC glucuronides (Gluc) including catechin-O-β-Gluc,
3′-O-methyl-catechin-O-β-Gluc, epicatechin-O-β-Gluc, and 3′-
O-methyl-epicatechin-O-β-Gluc; quercetin from juice resulted in
the accumulation of quercetin-Gluc, O- methyl quercetin-Gluc,
malvidin-glucoside (Glc), petunidin-Glc, delphinidin-Glc, and
peonidin-Glc; cyanidin-Glc from juice led to the plasma and
brain accumulation of malvidin-3-O-glucoside (Glc), petunidin-
3-O-Glc, delphinidin-3-O-Glc, peonidin-3-O-Glc, and cyanidin-
3-O-Glc; resveratrol led to the accumulation of resveratrol and
resveratrol Gluc in the brain. See Table 1 for detailed plasma PK
response and brain accumulation of polyphenol metabolites in
rats treated with Comb.
COMB TREATMENT IMPROVES SPECIAL MEMORY FUNCTION
We treated J20 mice with Resv, GSE, Juice, or Comb, starting
at 3 months of age. Treatments continued for 7 months until
mice were approximately 10 months of age. Consistent with our
previous studies (Wang et al., 2008; Vingtdeux et al., 2010), we
found that polyphenolic treatment from all groups were well-
tolerated; we observed no adverse effects in response to long-term
treatments as reflected by normal drinking, eating, grooming
behavior, and normal body weight (Figure 1).
The MWM test was used to evaluate cognitive function fol-
lowing treatment. In the hidden platform learning trial, we found
GSE treatment significantly improved the cognitive behavioral
performance of J20 mice, in comparison to age- gender-matched
non-treated, CTRL, J20 mice [F(1,13) = 3.726, p = 0.038 for GSE
treatment effect, Two-Way ANOVARM, Figure 2A]. Neither Resv
nor Juice treatment led to significant improvements in MWM
training trial (Figures 2B,C). The Combmice also performed sig-
nificantly better than the CTRLmice [F(1,14) = 6.627, p = 0.0231
for treatment effect, Two-Way ANOVA RM, Figure 2D].
Interestingly, compared to the CTRLmice, all groups of treated
J20 mice, except the Juice group, performed significantly bet-
ter in the probe trial phase of the MWM test 24 h after the last
training session (One-Way ANOVA, p = 0.021; GSE vs. CTRL,
∗p < 0.012; Resv vs. CTRL, ∗p < 0.012; Comb vs. CTRL, ∗∗p <
0.001, Figure 2E and Table 2 for statistical analysis). Juice group
performed better than the CTRL group, but did not reach sta-
tistical significance (p = 0.032, Figure 2E). Our data suggest that
GSE, Resv, Comb, and possibly Juice treatment lead to significant
improvement in spatial memory retention. In parallel control
studies (Figures 2F,G), we confirmed that all five groups of J20
mice performed equally well, excluding the possibility that the
polyphenol treatments might have affected non-spatial parame-
ters, such as sensorimotor performance and motivation, which
might have interfered with behavioral performance during the
MWM test.
DIFFERENTIAL EFFECT OF POLYPHENOL METABOLITES ON OAβ
INDUCED ACUTE SYNAPTIC DYSFUNCTION
LTP is one of the major cellular mechanisms that underlies
synaptic plasticity and is critical for learning and memory
(Bliss and Collingridge, 1993; Cooke and Bliss, 2006). Based
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FIGURE 1 | Chronic Comb treatment has no adverse effect body
weight measurements over the 5 month dietary treatment. Data
represents mean ± s.e.m., n = 8 − 9 per group.
on our observation that Resv and Juice treatment improved
memory retention in the J20 mice, we explored the possibil-
ity that accumulation of polyphenol metabolites in the brain,
following chronic polyphenol treatment, might directly con-
tribute to the cognitive benefits through the promotion of LTP.
We tested three metabolites that have been identified in the
brain following different dietary polyphenol treatment in mod-
ulating oAβ induced LTP deficits: 3′-O-Me-EC-Gluc from GSE,
cyanidin-Glc from Concord grape juice, and resveratrol. It is well
established that oAβ are potent synaptotoxins and can impair
synaptic plasticity. Hippocampal slices isolated from young mice
exhibited normal LTP response following tetanus stimulation
(Figure 3A), while 1-h bath perfusion of 200 nM oAβ com-
pletely inhibited LTP (Figure 3A). We found that 3′-O-Me-EC-
Gluc and cyanidin-Glc, applied at nanomolar concentrations,
significantly protects against acute oAβ-mediated LTP deficits
(Figures 3B,C). Co-treatment with 3′-O-Me-EC-Gluc resulted in
significantly increased LTP, expressed as a percentage of base-
line fEPSP slope compared with the vehicle treatment (196.7
± 6.5% vs. 151.8 ± 9.5 %, p < 0.01, Two-Way ANOVA). Co-
treatment with cyanidin-glc resulted in a significantly increased
LTP, expressed as a percentage of baseline fEPSP slope com-
pared with the vehicle treatment (216.7 ± 8.5 % vs. 151.8 ± 9.5
%, p < 0.01, Two-Way ANOVA). In contrast, the application of
resveratrol did not protect against oAβ-induced synaptic deficits
(Figure 3D). This observation revealed that select brain-targeted
metabolites from GSE and Concord grape juice extract are capa-
ble of directly protecting against AD-type oAβ-mediated synaptic
toxicity in the hippocampal formation and may contribute to the
improved cognitive function observed in the J20 mice.
COMB TREATMENT REDUCES BRAIN AMYLOID NEUROPATHOLOGY
Following MWM behavior assessment, we sacrificed the animals
and evaluated the impact of the different treatments on Aβ in
the brain. We found that both GSE and Comb treatment led
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FIGURE 2 | Chronic Comb treatment attenuates cognitive deterioration
in J20 mice. (A–D) The influence of chronic GSE, Resv, Juice, or Comb
treatment on Aβ-related spatial memory in J20 mice vs. untreated control
J20 mice in the Morris water maze test. Hidden platform acquisition: latency
score represents the time taken to escape to the platform from the water (E)
Spatial memory retention in the probe trial: percent of time in quadrant is
calculated as the ratio of time spent in the target quadrant area relative to the
time spent in the rest of the pool (quadrants: : target; 1-left; 2: opposite; 4:
right) (F) Cued platform visible trial (G) Average swimming speed. Data
represents mean ± s.e.m. n = 7 − 9 per group.
Table 2 | Significance of comparisons of the control treatment with
GSE, Resv, Juice, or Comb treatments.
Compared to CTRL Probe trial Aβ1–42 Aβ1–40 Amyloid
(memory retention) plaque
Grape seed extract 0.012* 0.023 0.020 0.023
Resveratrol 0.012* 0.968 0.284 0.892
Juice polyphenol extract 0.037 0.741 0.432 0.797
Combination treatment 0.001* 0.001** 0.007* 0.015
Statistical analysis of data from the probe trial, brain Aβ , and plaque burden
to compare the treatment groups vs. the control group, *p < 0.0125 (p <
0.05 adjusting for 4 comparisons); **p < 0.0025 (p < 0.01 adjusting for 4
comparisons).
to a reduced Aβ1−42 content in the brains, however, only the
Comb group reached statistical significance [One-Way ANOVA,
p = 0.0098; Comb vs. CTRL, ∗∗p < 0.001, F(1, 14) = 4.354,
Figure 4A and see Table 2 for statistical analysis]. Neither Juice
nor Resv treatment had any effect on brain Aβ1−42 levels
(Figure 4A). Similar results were obtained for the levels of Aβ1−40
[One-Way ANOVA, p = 0.0067; Comb vs. CTRL, ∗p < 0.007,
F(1, 14) = 3.152; Figure 4B and see Table 2 for statistical anal-
ysis]. Aβ1−42 peptides are more prone to aggregate and it is
believed the increased ratio of Aβ1−42/Aβ1−40 may contribute
to the pathogenesis of the disease. We found that polyphe-
nol treatment resulted in a reduced Aβ1−42/Aβ1−40 ratio in the
brain (One-Way ANOVA, p = 0.0112, Figure 4C), and both Juice
and Resv groups showed a strong trend of reduced ratio of
Aβ1−42/Aβ1−40 in the brain compared to the CTRL group (p =
0.06 for both groups). Plaque burden analysis revealed that GSE
treatment and Comb treatment reduced the load of plaques in
the hippocampal formation compared to the CTRL group, while
Resv and Juice had no effect (Figure 4D and see Table 2 for sta-
tistical analysis). Plasma amyloid peptide measurements showed
that none of the treatments had any effect on the levels of amyloid
peptides in the plasma (Figures 4E,F).
DISCUSSION
AD is a multifaceted disease and the etiology is largely unknown.
It is clinically characterized by progressive and degenerative mem-
ory loss and cognitive function, and pathologically characterized
by extracellular accumulation of neuritic plaques made of Aβ pro-
tein and neurofibrillary tangles (NFTs) composed of tau proteins
in the brain. AD is one of the most persistent and devastating
neurological disorders, and there is no effective treatment. Due
to the complexity of the disease and the limited knowledge of
how the disease starts and progresses, the search for a cure has
not been successful, despite tremendous efforts rendered by both
academic institutions and the pharmaceutical industry, with over
1000 clinical trials. There is a growing consensus that the fail-
ure to develop an effective intervention for AD may be due, in
part, to the fact that almost all past preclinical and clinical tri-
als have been designed to target individual pathological features,
which in the past two decades, mainly focus on various forms of
Aβ and APP processing. It is hypothesized that novel intervention
regimen(s) designed to simultaneously interfere with multiple
pathological features may yield a greater likelihood of therapeutic
efficacy.
In recent years, there is increasing interest to explore the poten-
tial value of plant derived polyphenols in treating neurological
disorders, including AD. There is accumulating evidence that
some of the pathophysiological effects associated with metabolic
syndrome are beneficially modulated by dietary supplementation
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FIGURE 3 | Select brain-penetrating polyphenolic metabolites from GSE
and Concord grape juice are bioactive in preventing acute oAβ-induced
LTP impairment. Ex vivo hippocampal slices from wild type (WT) mice were
acclimated in oxygenated artificial cerebrospinal fluid and challenged with (A)
200 nM of oAβ (B) 200 nM oAβ co-treated with 3′-O-Me-EC-Gluc (300 nM),
(C) 200 nM oAβ co-treated with cyanidin-Glur (300 nM) and (D) 200 nM oAβ
co-treated with resveratrol (20μM) for 1 h before recording. The fEPSPs were
recorded from the CA1 region. The fEPSP slopes (% of baseline) were
plotted as a function of time. The arrows indicate the beginning of tetanus
used to induce LTP. Inset in (A), representative EPSP traces for vehicle (left)
and oAβ (right) treated slices: Red trace represents pre-LTP and black trace
represents 60min following tetanus stimuli. Insets in (B) and (C), average
magnitude of LTP during the last 5min of recording. Data represents mean
± s.e.m., ∗∗P < 0.01.
of polyphenols (Marambaud et al., 2005; Rezai-Zadeh et al.,
2005; Ehrnhoefer et al., 2008; Ono et al., 2008; Rocha-Gonzalez
et al., 2008; Wang et al., 2008; Karuppagounder et al., 2009;
Thomas et al., 2009; Krikorian et al., 2010; Ho et al., 2011; Liu
et al., 2011; Capiralla et al., 2012). Majority of these studies were
focused on grape derived polyphenols, including resveratrol. One
of the major limitations of polyphenolic compounds for treating
neurological disorders is their complicated absorption, interac-
tion, metabolism, and eventually their bioavailability in targeted
organs, mainly the central nervous system. We carried out a
brain bioavailability study to explore whether oral administra-
tion of the combination of GSE, Resv, and Juice would alter the
metabolism and brain penetration of the compounds and their
metabolites. We found that all the metabolites identified in the
brains, through individual compound administration, were also
found in the brains of the rats treated with the Comb, suggesting
that these three compounds did not interfere with each other to
alter their absorption, metabolism, and brain penetration.
We compared the spatial memory function of J20 mice treated
with Comb or individual compounds to explore whether Comb
treatment can render additive or synergistic effects to improve
cognitive function. Consistent with our previous GSE study
(Wang et al., 2008), both GSE and Comb groups performed
well in learning trials, while the Resv and the Juice group did
not show appreciable improvements. All groups performed bet-
ter than the non-treated CTRL mice in the probe trial, with the
Comb treatment group showing slightly better performance than
the groups treated with individual polyphenols. Neuropathology
analysis also showed that the Comb group had much lower amy-
loid content and plaque burden compared to the CTRL mice.
However, the Resv and Juice had no effect on amyloid neu-
ropathology in the hippocampal formation. Our data seems to
be consistent with the observation reported by Vingtdeux et al.
(2010) that chronic resveratrol treatment does not reduce plaque
deposition in the hippocampus. However, their study demon-
strated that resveratrol treatment reduced both sodium dodecyl
sulfate (SDS) and formic acid fraction of Aβ in the brain. It is
possible that this difference is due to the different strains of mice
used (APP/PS1 vs. J20) or a different treatment regimen. To inves-
tigate the improvements of memory retention in the GSE, Resv,
and Juice treatment, we used electrophysiology to measure LTP,
one of the important mechanisms for long-term memory. We
found that select polyphenol metabolites from GSE and Juice
significantly improved acute oAβ-mediated LTP deficits in hip-
pocampal slices. Surprisingly, resveratrol, previously shown to be
able to increase phosphorylation of CREB (phosphor-Ser-133),
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FIGURE 4 | Chronic Comb treatment reduces brain neuropathology in
J20 mice (A,B) Quantification of total Aβ1−42 and Aβ1−40 in the brains
of GSE-, Resv-, Juice-, Comb-treated, or CTRL mice by ELISA
measurements (C) The ratio of Aβ1−42 to Aβ1−40 in the brains of GSE-,
Resv-, Juice-, Comb-treated, or CTRL mice. (D) Assessment of plaque
burden (percentage of area covered by plaques) in the hippocampus of the
J20 mice following chronic treatment. (E,F) Assessment of plasma levels of
amyloid peptides by ELISA. Data represents mean ± s.e.m., n = 8 − 9 per
group.
an important molecule involved in memory consolidation, did
not show any effect in restoring acute oAβ-mediated synaptic
toxicity.
In conclusion, our studies demonstrated that when delivered
in combination, the potentially bioactive metabolites from GSE,
resveratrol, and Concord juice extract can pass the blood brain
barrier and accumulate in the brain. We found that Comb treat-
ment provided better protection against amyloid neuropathology
and better preservation of cognitive function. We deduce that
the anti-amyloidogenic activities of the Comb treatment may
be mainly derived from GSE, while both GSE and Juice may
contribute to the improved cognitive function by improving
synaptic plasticity. There are many other amyloid-independent
mechanisms targeted by the individual polyphenol preparation
that may collectively contribute to improved cognitive function
and overall brain health. Both juice and resveratrol have strong
antioxidant and anti-inflammatory activities and can potentially
inhibit amyloid-mediated microglia activation (Capiralla et al.,
2012) or modulate inflammation-mediated blood brain barrier
dysfunction. However, the J20 mice used in the present study and
other existingmousemodels of amyloid pathology are inadequate
to address these questions, as they do not have similar, or as exten-
sive, inflammatory processes as humans. Future studies using
appropriate models, such as inflammation induction by injec-
tion of Poly I:C (Krstic et al., 2012) to both wild type and APP
mice, might be able to help us determine the anti-inflammation
activities of bioactive polyphenols and their role in AD disease
therapy.
Besides age and genetics, many factors contribute to the onset
and progression of AD. While Aβ proteins and NFTs are certainly
major culprits, oxidative stress and inflammation play impor-
tant roles in the pathogenesis of AD (Aisen and Davis, 1994;
Akiyama et al., 2000; Smith et al., 2000; Krstic et al., 2012; Kumar
and Foster, 2013; Lee et al., 2013). Given the increasing consen-
sus that multiple mechanisms during aging may synergistically
contribute to AD pathogenesis and cognitive decline, it is impor-
tant to continue investigating the role of combination therapies
in modulating synaptic plasticity, including BST and LTP, mito-
chondrial function, oxidative stress, and inflammation in models
of AD and aging, including experimental models of amyloid,
tau, chronic inflammation, and oxidative stress. Our future stud-
ies will focus on clarifying these mechanisms and continuing to
identify specific bioactive metabolite(s) and their mechanisms of
action for future application in preventing and treating AD and
other forms of dementia.
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